Multiple Sclerosis Market Forecast
Introduction
With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy. Although growth will be stifled by biosimilars, these new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years (20092019).
Reasons to Purchase
- Quantify the current and future size of the multiple sclerosis drug class market and understand the main commercial opportunities and threats
- Assess key marketed and pipeline drugs, including new oral agents, Acorda's Ampyra (dalfampridine) and GW Pharmaceuticals' Sativex (nabiximols).
- Understand the country-specific impact of key events in the multiple sclerosis market during the forecast period 2010 to 2019.
With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy. Although growth will be stifled by biosimilars, these new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years (20092019).
Reasons to Purchase
- Quantify the current and future size of the multiple sclerosis drug class market and understand the main commercial opportunities and threats
- Assess key marketed and pipeline drugs, including new oral agents, Acorda's Ampyra (dalfampridine) and GW Pharmaceuticals' Sativex (nabiximols).
- Understand the country-specific impact of key events in the multiple sclerosis market during the forecast period 2010 to 2019.